Search Results
May 22, 2026, 17:11 ET MEMORIAL DAY MARKS START OF SUMMER FITNESS RESET FOR LOS ANGELES PROFESSIONALS
confident and healthy going into summer, and that requires far more precision and accountability than people realize."While U.P. says GLP-1 medications can help people can lose weight rapidly, and there should be no stigma about using them, they can also lead to rapid loss of muscle,
More news about: Ultimate Performance
May 22, 2026, 11:14 ET Parker Waichman LLP Files Lawsuit on behalf of Florida Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a
More news about: Parker Waichman LLP
May 22, 2026, 10:31 ET Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
PlatformCXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost through injury, aging, and GLP-1-associated tissue-related weight loss. The first product expression, Ten Minute Tissue™, is a CXU-based injectable ECM that remains fluid at room temperature
More news about: USA News Group
May 21, 2026, 18:45 ET What drives multimillion-dollar medical claims? Sun Life report shows secondary health conditions, hospital stays and specialty drugs among key factors
million.Impact of GLP-1sMany high-dollar conditions are associated with obesity and diabetes. Employers have an opportunity to broaden coverage of GLP-1s and proactively reduce the risk of major health conditions that can result in high-dollar claims.While the cost of GLP-1s per
More news about: Sun Life U.S.
May 21, 2026, 14:35 ET Buying Outside the Pharmacy: 45% of Peptide Users Who Source From Social Media Have Visited the ER
Market Report, revealing a fast-growing population of U.S. adults buying injectable peptides outside the regulated pharmacy system. While GLP-1 weight-loss drugs like Ozempic have dominated peptide coverage, the survey of 1,000 U.S. peptide users finds that the broader peptide market includes
More news about: Sunlight
May 21, 2026, 12:38 ET /C O R R E C T I O N -- FlyteHealth/
utilization across several healthcare service categoriesMore responsible management of prescription drug spending, including GLP-1-related costs, through clinically guided medication stewardshipImprovements associated with cardiovascular and broader cardiometabolic health
More news about: FlyteHealth
May 21, 2026, 11:38 ET Twin Health Introduces Precision GLP-1 Stewardship Model, Helping Members Lose More Weight Without Long-Term Dependence
Platform for cardiometabolic health, today announced the launch of its GLP-1 Stewardship Model to reduce long-term dependence on GLP-1s. The Digital Twin Care Platform enables a precision approach to GLP-1 use for weight loss that shortens treatment duration, sustains weight loss,
More news about: Twin Health
May 21, 2026, 11:15 ET Canvas Medical Launches Studio to Enable Clinicians and Operators to Customize and Extend EMR Workflows in Canvas
for patient follow-up based on specified quantitative thresholds of results. A weight-loss practice could create context-aware automation of GLP-1 treatment plans, enabling standing orders for common treatment programs. These reduce costly back and forth within the practice and reduce cognitive
More news about: Canvas Medical
May 21, 2026, 11:00 ET Synakis Announces Close of Oversubscribed Pre-Seed Round
million pre-seed financing round to advance SNK-125, its vitreous replacement therapy for retinal detachment. Proceeds will support completion of GLP toxicology studies by early 2027 for an Investigational Testing Authorization (ITA) filing with Health Canada, and lead optimization for ocular therapeutic
More news about: Synakis
May 21, 2026, 09:15 ET Wellness Clinic Prana IV Therapy Discusses Nutritional Gaps Linked to GLP-1 Weight Loss Drugs
Deficiencies Associated With GLP-1 Receptor Agonist Therapy found that vitamin D deficiency was the most common nutritional issue. It also identified iron deficiency, B vitamin deficiency, protein insufficiency, and calcium deficiency among GLP-1 users.More than 60% of
More news about: Prana IV Therapy
May 21, 2026, 09:00 ET Foodsmart Completes Executive Leadership Team with Product and Commercial Leaders to Scale Foodcare Nationwide
members receiving medical nutrition therapy and medically tailored food.GLP-1 + Medical Nutrition Therapy: Amplifying Outcomes, Offsetting CostsFor GLP-1 therapy, now the fastest-growing category in Medicaid pharmacy spending, members who received
More news about: Foodsmart
May 21, 2026, 07:05 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is
More news about: Viking Therapeutics, Inc.
May 21, 2026, 06:45 ET Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes.
More news about: Eli Lilly and Company
May 20, 2026, 09:00 ET Maven Expands Virtual Clinic Nationwide, Integrating GLP-1 and Hormonal Care With Comprehensive Women's Health
in the country can seek access to GLP-1s or hormone therapy on-demand — alongside the guidance they need to manage these therapies with a nuanced understanding of their own bodies and objectives."A system built for prescriptions, not patientsGLP-1s and hormone therapy have transformed
More news about: Maven Clinic
May 20, 2026, 08:00 ET MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor
More news about: MetaVia Inc.
May 19, 2026, 15:43 ET New Clinical Study Shows Pasteurized Akkermansia muciniphila MucT Supports Weight Loss Maintenance
Findings underscore growing need for long-term weight maintenance strategies in the GLP-1 EraWILMINGTON, Del., May 19, 2026 /PRNewswire/ -- The Akkermansia Company
More news about: The Akkermansia Company
May 19, 2026, 12:23 ET TERREPOWER demuestra la descarbonización en su Informe de Sostenibilidad Corporativa de 2025
de electricidad para una de las operaciones europeas de TERREPOWER con mayor intensidad de carbono.El continuo progreso en la transición del GLP al gas natural, iniciada en 2024, contribuye a estabilizar las emisiones de Alcance 1 a pesar del crecimiento operativo.La empresa también
More news about: TERREPOWER
May 19, 2026, 12:19 ET TERREPOWER Demonstra Descarbonização e Eficiência de Recursos em Escala no Relatório de Sustentabilidade Corporativa 2025
energia elétrica garantidas para uma das operações europeias da TERREPOWER com maior intensidade de carbonoAvanço contínuo na transição de GLP para o gás natural, iniciada em 2024, ajudando a estabilizar as emissões do Escopo 1 apesar do crescimento operacionalA empresa também aprofundou
More news about: TERREPOWER
May 19, 2026, 10:17 ET TERREPOWER demuestra la descarbonización y la eficiencia de los recursos a escala en el Informe de Sostenibilidad Corporativa 2025
electricidad aseguradas para una de las operaciones europeas más intensivas en carbono de TERREPOWERProgreso continuo en la transición del GLP al gas natural, iniciado en 2024, que ayuda a estabilizar las emisiones de Alcance 1 a pesar del crecimiento operativoLa empresa también
More news about: TERREPOWER
May 19, 2026, 10:00 ET Two Pharma Companies Now Own Nearly 100% of GLP-1 Citations Inside ChatGPT, Claude and Perplexity, New 5W Index Finds
framed in AI answers as "before GLP-1s, people tried...". Meal delivery is being recategorized as an adjunct to medication-based weight loss. The OTC supplement category — Hydroxycut, Leanbean, PhenQ and Garcinia products — has lost nearly all generic citation share to GLP-1s and Plenity, with AI models
More news about: 5W Public Relations
May 19, 2026, 10:00 ET Hearst Magazines Hosts 3rd Annual Women's Health Lab in Partnership With Northwell's Katz Institute for Women's Health
Ipsen)Skin in Transition: The GLP-1 Effect on Skin—Science, Stories & Solutions – Women's Health Beauty Director Brian Underwood moderated a discussion examining the emerging impact of GLP-1 medications on skin, including the stigma and public
More news about: Hearst Magazines
May 19, 2026, 09:00 ET The Protein Snack That Starts with Dessert: Novus Foods Introduces Winky Protein Pudding
that actually tastes good. According to Numerator, dessert snack sales among GLP-1 households are up 27% compared to just 1.8% growth among non-GLP-1 households in 2025 — with GLP-1 shoppers eating more intentionally and spending more per unit, a clear signal that
More news about: Novus Foods
May 19, 2026, 01:19 ET Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic Effects
fields.The presentation covered animal study results of CBL-514 in combination with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide. The results showed that CBL-514, when combined with GLP-1R-based weight-loss therapies, demonstrated four complementary and synergistic potentials
More news about: Caliway Biopharmaceuticals
May 18, 2026, 08:31 ET MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
(OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR),
More news about: MetaVia Inc.
May 18, 2026, 04:31 ET 康霈首登 ECO 2026 口頭發表 CBL-514 併用 GLP-1R 類減重藥物動物數據 全身性代謝效果吸引國際專家及大藥廠高度興趣
score）等肝臟傷害相關指標改善。此結果顯示，CBL-514 與 GLP-1R 類減重藥物併用，在動物實驗中除體重維持與脂肪減少外，亦呈現改善肝臟代謝與發炎狀態之潛在科學意義。康霈副總鍾琭璣表示：「我們很榮幸由 Dr. Sharma 這樣具國際影響力的肥胖醫學權威，於 ECO 2026 向全球肥胖與代謝領域專家發表 CBL-514 與 GLP-1R 類減重藥物併用之動物實驗數據。本次口頭發表現場參與度高，吸引超過300位聽眾，包括跨國藥廠代表、臨床醫師、專家學者及產業人士，有助於提升 CBL-514 在國際肥胖與代謝領域的能見度，並深化與關鍵潛在合作夥伴的交流。」鍾琭璣副總進一步指出：「隨著 GLP-1R 類
More news about: 康霈生技